Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Seelos Therapeutics - Stock

Seelos Therapeutics Stock

SEEL
US81577F1093
A2PDK8

Price

0.56
Today +/-
+0
Today %
+0 %
P

Seelos Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Seelos Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Seelos Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Seelos Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Seelos Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Seelos Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Seelos Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Seelos Therapeutics’s growth potential.

Seelos Therapeutics Revenue, EBIT and net profit per share

DateSeelos Therapeutics RevenueSeelos Therapeutics EBITSeelos Therapeutics Net Income
2028e370.24 M undefined0 undefined0 undefined
2027e258.92 M undefined6.02 M undefined0 undefined
2026e206.96 M undefined-31.82 M undefined-1.31 M undefined
2025e28.97 M undefined-63.55 M undefined-851,904 undefined
2024e306,000 undefined-36.62 M undefined-3.49 M undefined
20232.2 M undefined-40.5 M undefined-37.88 M undefined
20220 undefined-70.92 M undefined-73.53 M undefined
20210 undefined-61.67 M undefined-66.05 M undefined
20200 undefined-18.76 M undefined-19.1 M undefined
2019375,000 undefined-29.75 M undefined-51.26 M undefined
20180 undefined-3.18 M undefined-3.48 M undefined
20170 undefined-10.67 M undefined321,000 undefined
20160 undefined-13.66 M undefined-7.43 M undefined
20154.84 M undefined-21.25 M undefined-19.02 M undefined
20149.26 M undefined-24.37 M undefined-21.79 M undefined
20132.51 M undefined-18.79 M undefined-16.94 M undefined
20127.95 M undefined-14.21 M undefined-31.77 M undefined
20113.6 M undefined-15.53 M undefined-18.12 M undefined
20104.97 M undefined-11.23 M undefined-29.51 M undefined
20092.97 M undefined-3.27 M undefined-32.04 M undefined
20085.96 M undefined-4.27 M undefined-5.17 M undefined
20071.27 M undefined-9.39 M undefined-8.79 M undefined
20061.87 M undefined-9.13 M undefined-8.11 M undefined
20052.4 M undefined-15.7 M undefined-16.55 M undefined
2004360,000 undefined-17.3 M undefined-17.02 M undefined

Seelos Therapeutics Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
0051000002115243729400000002028206258370
----80.00-------50.00-400.00-60.00100.00-25.00133.33-71.43350.00-55.56----------635.7125.2443.41
-----------100.00100.00100.0025.0033.3342.86-88.8975.00-------------
000000000001521130830000000000000
-3-3-4-4-10-17-27-14-17-15-9-9-4-3-11-15-14-18-24-21-13-10-3-29-18-61-70-40-36-63-3160
---80.00-400.00------750.00-900.00-900.00-80.00-150.00-275.00-500.00-200.00-900.00-266.67-525.00--------2,000.00--225.00-15.052.33-
-3-3-4-2-8-16-27-20-17-16-8-8-5-32-29-18-31-16-21-19-70-3-51-19-66-73-37-30-100
--33.33-50.00300.00100.0068.75-25.93-15.00-5.88-50.00--37.50540.00-9.38-37.9372.22-48.3931.25-9.52-63.16--1,600.00-62.75247.3710.61-49.32-91.89----
0000000000.10.10.10.10.10.20.30.40.50.60.70.91.712.884.6186.5378.7443.1612.500000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Seelos Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Seelos Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Seelos Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Seelos Therapeutics's financial health and stability.

Assets

Seelos Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Seelos Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Seelos Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Seelos Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-3-3-4-2-8-16-27-17-17-15-8-8-5-32-29-18-31-16-21-19-70-3-51-19-66-73-37
00000001,0001,0000000000000000000000
0000000000000000000000000000
0000203-304-20000200-1-2-1-116-4-1212
200-10003102142923519460-2-8125426141
0000000000000000000000000000
0000000000000000000000000000
-1-3-5-4-6-14-23-15-15-9-6-6-2-3-6-9-14-15-18-22-13-10-1-19-20-49-61-23
0000-3-4-4000000000000000000000
0-110-11-200000000001400012000000
0-110-8240000000001500012000000
0000000000000000000000000000
0220015600-1-210300014-3-71011-13-1-7
122840151814416000127201651014902915125019
1457402112513415-120157201671511212926112-111
----------------------------
0000000000000000000000000000
001322-14-119-2-48-80-28-176-10-7-14010563-63-12
-1.15-3.2-5.67-4.71-9.63-19.07-27.93-15.98-15.38-10-6.75-6.69-2.74-3.37-7.33-9.98-14.82-15.64-18.6-22.98-13.09-10.47-1.58-19.31-20.91-49-61.6-23.91
0000000000000000000000000000

Seelos Therapeutics stock margins

The Seelos Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Seelos Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Seelos Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Seelos Therapeutics's sales revenue. A higher gross margin percentage indicates that the Seelos Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Seelos Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Seelos Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Seelos Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Seelos Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Seelos Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Seelos Therapeutics Margin History

Seelos Therapeutics Gross marginSeelos Therapeutics Profit marginSeelos Therapeutics EBIT marginSeelos Therapeutics Profit margin
2028e80.95 %0 %0 %
2027e80.95 %2.32 %0 %
2026e80.95 %-15.38 %-0.63 %
2025e80.95 %-219.37 %-2.94 %
2024e80.95 %-11,966.67 %-1,139.7 %
202380.95 %-1,838.36 %-1,719.56 %
202280.95 %0 %0 %
202180.95 %0 %0 %
202080.95 %0 %0 %
201980.95 %-7,932.53 %-13,668 %
201880.95 %0 %0 %
201780.95 %0 %0 %
201680.95 %0 %0 %
201580.95 %-439.1 %-393.12 %
201490.09 %-263.15 %-235.3 %
2013-4.78 %-748.5 %-674.55 %
201246.63 %-178.8 %-399.89 %
201148.43 %-430.95 %-502.83 %
201020.71 %-225.88 %-593.36 %
200995.69 %-109.93 %-1,077.53 %
2008100 %-71.68 %-86.82 %
2007100 %-739.13 %-691.89 %
200680.95 %-488.97 %-434.33 %
200580.95 %-654.48 %-689.87 %
2004100 %-4,806.67 %-4,728.61 %

Seelos Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Seelos Therapeutics earnings per share therefore indicates how much revenue Seelos Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Seelos Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Seelos Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Seelos Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Seelos Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Seelos Therapeutics Revenue, EBIT and net profit per share

DateSeelos Therapeutics Sales per ShareSeelos Therapeutics EBIT per shareSeelos Therapeutics Earnings per Share
2028e141.85 undefined0 undefined0 undefined
2027e99.2 undefined0 undefined0 undefined
2026e79.3 undefined0 undefined-0.5 undefined
2025e11.1 undefined0 undefined-0.33 undefined
2024e0.12 undefined0 undefined-1.34 undefined
20233.6 undefined-66.12 undefined-61.85 undefined
20220 undefined-160.05 undefined-165.95 undefined
20210 undefined-162.84 undefined-174.41 undefined
20200 undefined-100.58 undefined-102.42 undefined
20194.43 undefined-351.62 undefined-605.85 undefined
20180 undefined-248.75 undefined-271.48 undefined
20170 undefined-6,278.24 undefined188.82 undefined
20160 undefined-15,175.56 undefined-8,258.89 undefined
20156,912.86 undefined-30,354.29 undefined-27,175.72 undefined
201415,431.67 undefined-40,608.33 undefined-36,310 undefined
20135,022 undefined-37,589.8 undefined-33,876 undefined
201219,862.5 undefined-35,515 undefined-79,427.5 undefined
201112,010 undefined-51,756.66 undefined-60,390 undefined
201024,865 undefined-56,165 undefined-147,540 undefined
200929,737 undefined-32,689 undefined-320,426 undefined
200859,570 undefined-42,700 undefined-51,720 undefined
200712,700 undefined-93,870 undefined-87,870 undefined
200618,670 undefined-91,290 undefined-81,090.01 undefined
200523,990 undefined-157,010 undefined-165,500 undefined
20040 undefined0 undefined0 undefined

Seelos Therapeutics business model

Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. The company was founded in 2016 by Raj Mehra and is headquartered in New York City. Seelos Therapeutics Inc specializes in the development of therapeutics for neurological and psychiatric disorders, with a focus on treating patients with severe, chronic, or life-threatening conditions. The company has developed an innovative business model based on collaboration with various institutions, organizations, and companies. The company is divided into several divisions, including clinical development, product development, technology development, and strategic partnerships. Each division focuses on specific aspects of therapy development and contributes to Seelos' ability to develop innovative and effective therapeutics for its patients. In the clinical development division, Seelos Therapeutics Inc focuses on conducting clinical trials to assess the efficacy and safety of its therapeutics. The company works closely with various academic institutions and clinics to conduct its clinical studies and ensure they adhere to the highest scientific standards. The product development division is responsible for the development of Seelos' actual therapeutics. It encompasses research, development, manufacturing, and quality assurance of the company's products. Seelos emphasizes rigorous quality and safety management to ensure its products meet the highest standards. In the technology development division, Seelos focuses on developing innovative technologies for therapy development. In collaboration with various institutions and companies, the company invests in the development of new technologies to improve its therapeutics and optimize patient care. A crucial aspect of Seelos' business model is collaboration with other companies and institutions. The company has formed strategic partnerships with various institutions and companies in the biotechnology and pharmaceutical fields. This allows Seelos to leverage the expertise and resources of other companies and expedite the development of its therapeutics. Seelos' flagship product is SLS-002, a novel rapid-onset nasal ketamine for the treatment of suicidality in patients with depression and bipolar disorder. SLS-002 has shown promising results in clinical trials and is currently in Phase 2b of clinical development. Seelos is also working on the development of therapeutics for other neurological and psychiatric disorders, such as Huntington's disease, neuropathic pain, and Amyotrophic Lateral Sclerosis (ALS). Overall, Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. Through its innovative business model and collaboration with other companies and institutions, Seelos aims to expedite the development of its therapeutics and improve the lives of patients with severe, chronic, or life-threatening conditions. Seelos Therapeutics is one of the most popular companies on Eulerpool.com.

Seelos Therapeutics SWOT Analysis

Strengths

Seelos Therapeutics Inc boasts a robust pipeline of innovative therapeutic candidates and a diverse product portfolio. This provides the company with a competitive advantage, as it can cater to various medical needs and tap into multiple markets.

Seelos Therapeutics Inc has established strategic partnerships with leading pharmaceutical companies, academic institutions, and research organizations. These collaborations enable the company to leverage shared knowledge, resources, and expertise, fostering the development of groundbreaking therapies and enhancing market reach.

The company's research and development capabilities are a key strength, with a talented team of scientists and researchers dedicated to advancing therapeutic innovations. Seelos Therapeutics Inc invests significantly in R&D, ensuring continuous improvements in its product pipeline and staying at the forefront of medical science.

Weaknesses

The pharmaceutical industry is subject to strict regulatory controls, and Seelos Therapeutics Inc may face challenges in obtaining necessary approvals for its products. Additionally, clinical trials carry inherent risks, such as unforeseen complications or failure to meet efficacy endpoints, which can lead to delays or setbacks.

Seelos Therapeutics Inc currently has limited market presence compared to well-established competitors. Establishing brand recognition and expanding market share may require significant marketing efforts and investment to overcome the challenges posed by well-established players.

Opportunities

As the healthcare industry continues to evolve, there is an increasing demand for innovative therapies that can provide better treatment options, improved outcomes, and enhanced patient experiences. Seelos Therapeutics Inc can capitalize on this opportunity by leveraging its strong pipeline and delivering breakthrough solutions to address unmet medical needs.

Seelos Therapeutics Inc has the potential to expand its market presence by targeting untapped markets or regions with high disease prevalence and limited treatment options. By strategically identifying such areas, the company can establish a competitive advantage and capture new market share.

Threats

The pharmaceutical industry is highly competitive, with numerous players vying for market share. Seelos Therapeutics Inc faces the threat of new entrants, as well as competition from established companies with significant resources and established brands. Sustaining a competitive edge and gaining market acceptance can be challenging.

Rapidly evolving regulations in the pharmaceutical industry pose a threat to Seelos Therapeutics Inc. Changes in reimbursement policies, pricing pressures, and stricter compliance requirements can impact the company's profitability and ability to bring its products to market.

Seelos Therapeutics valuation based on historical P/E ratio, EBIT, and P/S ratio.

Seelos Therapeutics shares outstanding

The number of shares was Seelos Therapeutics in 2023 — This indicates how many shares 612,500 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Seelos Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Seelos Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Seelos Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Seelos Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Seelos Therapeutics Stock splits

In Seelos Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Seelos Therapeutics.

Seelos Therapeutics Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2023-6.53 -6.32  (3.19 %)2023 Q4
9/30/2023-14.69 -28.8  (-96.08 %)2023 Q3
6/30/2023-2.86 -6.6  (-131.1 %)2023 Q2
3/31/2023-3.37 -3.6  (-6.95 %)2023 Q1
12/31/2022-3.98 -5.1  (-28.21 %)2022 Q4
9/30/2022-3.21 -5.4  (-68.07 %)2022 Q3
6/30/2022-0.15 -0.2  (-36.8 %)2022 Q2
3/31/2022-0.18 -0.13  (29.19 %)2022 Q1
12/31/2021-0.11 -0.28  (-149.55 %)2021 Q4
9/30/2021-0.09 -0.11  (-26.87 %)2021 Q3
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Seelos Therapeutics stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

31

👫 Social

29

🏛️ Governance

25

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Seelos Therapeutics Stock Shareholders

%
Name
Stocks
Change
Date
8.76 % Wealth Effects LLC228,593108,41812/31/2023
7.09 % Mehra Raj185,14302/21/2024
6.94 % AdvisorShares Investments, LLC181,259160,54812/31/2023
4.28 % Tontine Asset Management, LLC111,615-113,20512/31/2023
35.11 % The Lind Partners, LLC916,36502/21/2024
3.33 % Golembiewski (Michael Joseph)86,8694172/29/2024
2.67 % Modera Wealth Management, LLC69,72828,93512/31/2023
2.67 % Morgan Stanley Smith Barney LLC69,61353,72412/31/2023
2.14 % BlackRock Institutional Trust Company, N.A.55,964-50212/31/2023
11.64 % Mirae Asset Global Investments (USA) LLC303,714273,72212/31/2023
1
2
3
4
5
...
10

Seelos Therapeutics Executives and Management Board

Dr. Raj Mehra63
Seelos Therapeutics Chairman of the Board, President, Chief Executive Officer (since 2019)
Compensation 2.46 M
Mr. Michael Golembiewski51
Seelos Therapeutics Chief Financial Officer
Compensation 1.07 M
Dr. Brian Lian57
Seelos Therapeutics Independent Director
Compensation 115,273
Dr. Margaret Dalesandro76
Seelos Therapeutics Independent Director
Compensation 98,992
Mr. Richard Pascoe58
Seelos Therapeutics Independent Director (since 2013)
Compensation 95,833
1
2

Seelos Therapeutics stock: Frequently Asked Questions

What values and corporate philosophy does Seelos Therapeutics represent?

Seelos Therapeutics Inc represents values of patient-centricity, innovation, and dedication to improving the lives of individuals affected by devastating neurological and psychiatric disorders. The company aims to develop innovative therapies using advanced technologies to address unmet medical needs. Seelos Therapeutics Inc is committed to scientific excellence, maintaining high ethical standards, and fostering a culture of collaboration and integrity. With a focus on research, development, and commercialization of novel therapies, Seelos Therapeutics Inc strives to become a leading player in the pharmaceutical industry, delivering effective solutions for the benefit of patients worldwide.

In which countries and regions is Seelos Therapeutics primarily present?

Seelos Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Seelos Therapeutics achieved?

Some significant milestones achieved by Seelos Therapeutics Inc include the successful completion of a Phase III clinical trial for their lead product candidate, SLS-002, in patients with acute suicidal ideation and behavior. This trial demonstrated positive results, showing a rapid and sustained reduction in suicidal ideation. Additionally, Seelos Therapeutics has received FDA Fast Track designation for SLS-002, recognizing its potential to address a critical unmet need in this patient population. The company has also expanded its pipeline with the initiation of clinical trials for other innovative therapies targeting central nervous system disorders.

What is the history and background of the company Seelos Therapeutics?

Seelos Therapeutics Inc, a leading biopharmaceutical company, has a rich history and promising background. Established with a focus on developing groundbreaking treatments, Seelos Therapeutics Inc has consistently shown dedication towards advancing healthcare solutions. With a diverse pipeline of innovative therapeutics, the company aims to address critical unmet medical needs in neurological and psychiatric disorders. Seelos Therapeutics Inc is constantly engaged in research and development activities to provide effective solutions for conditions such as Parkinson's disease and Sanfilippo syndrome. Their commitment to improving patients' lives, coupled with a talented team of experts, positions Seelos Therapeutics Inc amongst the industry frontrunners, driving advancements and bringing hope to those in need.

Who are the main competitors of Seelos Therapeutics in the market?

Some of the main competitors of Seelos Therapeutics Inc in the market include Biogen Inc, Johnson & Johnson, AbbVie Inc, and Novartis AG.

In which industries is Seelos Therapeutics primarily active?

Seelos Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Seelos Therapeutics?

The business model of Seelos Therapeutics Inc. revolves around the development of innovative pharmaceutical products to address unmet medical needs. Seelos Therapeutics focuses on the research, clinical development, and commercialization of potentially life-changing therapies for neuropsychiatric and neurologic disorders. The company prioritizes the identification and acquisition of promising assets and advances them through rigorous clinical trials to obtain regulatory approval. By successfully bridging the gap between research and commercialization, Seelos Therapeutics aims to deliver effective treatments and improve the quality of life for patients suffering from various neurological disorders.

What is the P/E ratio of Seelos Therapeutics 2024?

The Seelos Therapeutics P/E ratio is -0.1.

What is the P/S ratio of Seelos Therapeutics 2024?

The Seelos Therapeutics P/S ratio is 1.11.

What is the AlleAktien quality score of Seelos Therapeutics?

The AlleAktien quality score for Seelos Therapeutics is 5/10.

What is the revenue of Seelos Therapeutics 2024?

The expected Seelos Therapeutics revenue is 306,000 USD.

How high is the profit of Seelos Therapeutics 2024?

The expected Seelos Therapeutics profit is -3.49 M USD.

What is the business model of Seelos Therapeutics

Seelos Therapeutics Inc is an innovative biotechnology company specializing in the development of novel therapies for neurological and mental disorders. The company was founded in 2018 and is headquartered in New York City. The business model of Seelos Therapeutics is based on identifying promising drug candidates that are tested for safety and efficacy in clinical trials. The company works closely with leading experts in neurology and psychiatry to ensure the best possible research and development of medications. Seelos Therapeutics' product portfolio currently includes several promising candidates for the treatment of neuropsychiatric disorders, based on different technologies. One of the company's most important products is SLS-002, an intranasal ketamine spray for the treatment of depression and suicidality. The experimental drug is currently in Phase IIb evaluation. The company has also developed SEEL-011, a clinical candidate for the treatment of acute suicide risk using a patched formulation for the administration of Alprazolam. The feasibility and safety of the product have been demonstrated in Phase I evaluation and it is currently being tested for efficacy in Phase II evaluation. Other significant products of Seelos Therapeutics include SLS-007, a neuropeptide FYGH16 agonist for the treatment of central apneas in patients with amyotrophic lateral sclerosis (ALS), and SLS-004, a topoisomerase inhibitor for the treatment of acute myeloid leukemia (AML). Both products have been acquired by the company from Mount Sinai Health System. The company benefits from an established network of scientists and clinics that collaborate closely with the company to continue the research and development of promising drug candidates. The company also works closely with regulatory authorities to ensure successful market approval of its products. In addition, Seelos Therapeutics is also seeking to diversify its business activities by entering into partnerships and licensing agreements with other pharmaceutical companies and technology providers. For example, the company has signed a collaboration agreement with HitGen Inc. to accelerate the discovery of drug candidates. In summary, the business model of Seelos Therapeutics is based on identifying promising drug candidates for neurological and psychiatric disorders, which are developed through close collaboration with experts, innovative technologies, and methods. This allows the company to contribute to improving treatment options for patients in this field.

What is the Seelos Therapeutics dividend?

Seelos Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Seelos Therapeutics pay dividends?

The dividend cannot currently be calculated for Seelos Therapeutics or the company does not pay out a dividend.

What is the Seelos Therapeutics ISIN?

The ISIN of Seelos Therapeutics is US81577F1093.

What is the Seelos Therapeutics WKN?

The WKN of Seelos Therapeutics is A2PDK8.

What is the Seelos Therapeutics ticker?

The ticker of Seelos Therapeutics is SEEL.

How much dividend does Seelos Therapeutics pay?

Over the past 12 months, Seelos Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seelos Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seelos Therapeutics?

The current dividend yield of Seelos Therapeutics is .

When does Seelos Therapeutics pay dividends?

Seelos Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seelos Therapeutics?

Seelos Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seelos Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seelos Therapeutics located?

Seelos Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seelos Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seelos Therapeutics from 7/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Seelos Therapeutics pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of Seelos Therapeutics in the year 2023?

In the year 2023, Seelos Therapeutics distributed 0 USD as dividends.

In which currency does Seelos Therapeutics pay out the dividend?

The dividends of Seelos Therapeutics are distributed in USD.

Other fundamentals and analyses of Seelos Therapeutics in the deep dive.

Our stock analysis for Seelos Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seelos Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.